Teva, Nuvelution to partner on Tourette's syndrome drug study | DePuy Synthes to sell Prodisc assets to Centinel Spine | DOD taps Hill-Rom for $45M supplies contract
September 21, 2017
Aon Life Sciences Advisor
Top Stories
Teva, Nuvelution to partner on Tourette's syndrome drug study
Teva Pharmaceutical Industries agreed to collaborate with Nuvelution Pharma in advancing the development of Austedo, or deutetrabenazine, as a treatment for patients with Tourette's syndrome. Teva will be responsible for the regulatory process and commercialization of Austedo, which is expected to be under a late-stage study in fourth quarter of the year, while Nuvelution will fund the clinical trials.
Seeking Alpha (free registration) (9/19) 
LinkedIn Twitter Facebook Google+ Email
DePuy Synthes to sell Prodisc assets to Centinel Spine
An agreement was reached by Centinel Spine to buy the Prodisc-C, Prodisc-L, Prodisc-C Nova, Prodisc-C Vivo, Prodisc-O and Discover cervical and lumbar artificial disc systems from Johnson & Johnson subsidiary DePuy Synthes for undisclosed terms. The transaction is expected to be completed in the fourth quarter.
MassDevice (Boston) (9/19) 
LinkedIn Twitter Facebook Google+ Email
Other News
Liability and Safety
State AGs go after opioids manufacturers, distributors
The attorneys general of 41 states collectively issued subpoenas to manufacturers and distributors of opioid drugs, seeking information on marketing to health care professionals and patients. The AGs seek "to uncover whether or not there was deception involved, if manufacturers misled doctors and patients about the efficacy and addictive power of these drugs," said New York Attorney General Eric Schneiderman.
National Public Radio (9/19) 
LinkedIn Twitter Facebook Google+ Email
Business and Market Trends
Uncertainty, opportunities in biosimilars market
The market for biologic and biosimilar drugs is full of both opportunities and uncertainties regarding competition, adoption and pricing, according to Yogesh Soneji of Trinity Partners. Companies will compete in both the branded biologics and biosimilars spaces, he said, and biosimilars will eventually drive down prices.
Specialty Pharmacy Times (9/18) 
LinkedIn Twitter Facebook Google+ Email
Regulatory approval doesn't mean biosimilars are available
Only three of the seven FDA-approved biosimilar drugs are available for sale in the US. The others are the subject of patent disputes that may block their sale for years.
Bloomberg (9/18) 
LinkedIn Twitter Facebook Google+ Email
Other News
Government and Regulatory
Health Care and Policy
FDA to post REMS inquiries
The FDA will publicly release letters the agency sends when generic-drug makers ask the FDA for permission to obtain samples of brand-name drugs for bioequivalence testing. The policy is part of a push to prevent drugmakers from using Risk Evaluation and Mitigation Strategies to withhold samples and prevent generic competition.
Regulatory Focus (9/14) 
LinkedIn Twitter Facebook Google+ Email
Other News
News from Aon
Despite job-growth surge, US workers' pay, bonuses unlikely to rise much in 2018
Despite a strengthening economy and high job rates, most US workers are unlikely to see sizable increases in their salaries for 2018, according to Aon's 2017 US Salary Increase Survey of 1,062 US companies. It expects base pay to be 3% in 2018, up slightly from 2.9% in 2017. Read more.
LinkedIn Twitter Facebook Google+ Email
Money for nothing: Are we ready to go cashless?
"After hundreds of years of paper notes and cashiers in our banks, I predict that we will be cashless and digital within the next 30 years," says John Brosnan, head of Financial Services Group, Aon Risk Solutions. The Financial Times has described cash as a "barbarous relic" and around the world; digital cryptocurrencies compete to provide people with what is designed to be a completely decentralized currency. Understanding why people are looking to stop circulating cash and what the advantages and pitfalls could be is becoming increasingly important. Read more.
LinkedIn Twitter Facebook Google+ Email
Going to bed at night saying we've done something wonderful ... that's what matters to me.
Steve Jobs,
LinkedIn Twitter Facebook Google+ Email
Learn more about Aon Life Sciences:
Aon Home Page | Aon Life Sciences
Thought Leadership | Media Room
About Aon Life Sciences Practice
Aon provides Life Sciences companies with end-to-end risk solutions, supporting organizations from the initial discovery phase to final product launch. The practice provides solutions across the Life Sciences for pharmaceutical manufacturers; generic and OTC pharmaceutical companies; biotechnology and biopharmaceutical companies; genomic and proteomic companies; drug delivery system; diagnostic substance companies; and medical device and equipment manufacturers.

Contact Aon
Aon Risk Solutions – Life Sciences
James Walters, Global Practice Leader

 Linkedin Twitter
About Aon
Aon plc (NYSE:AON) is a leading global professional services firm providing a broad range of risk, retirement and health solutions. Our 50,000 colleagues in 120 countries empower results for clients by using proprietary data and analytics to deliver insights that reduce volatility and improve performance.
Powered By SmartBrief
Subscriber Tools:
Contact Us:
Editor  -  Tara Rosenzweig
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2017 SmartBrief, Inc.®
Privacy policy |  Legal Information